An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.

Neurofibromatosis type 1 (NF1) is characterized by cafe-au-lait spots, skinfold freckling, and cutaneous neurofibromas. No obvious relationships between small mutations (<20 bp) of the NF1 gene and a specific phenotype have previously been demonstrated, which suggests that interaction with either unlinked modifying genes and/or the normal NF1 allele may be involved in the development of the particular clinical features associated with NF1. We identified 21 unrelated probands with NF1 (14 familial and 7 sporadic cases) who were all found to have the same c.2970-2972 delAAT (p.990delM) mutation but no cutaneous neurofibromas or clinically obvious plexiform neurofibromas. Molecular analysis identified the same 3-bp inframe deletion (c.2970-2972 delAAT) in exon 17 of the NF1 gene in all affected subjects. The Delta AAT mutation is predicted to result in the loss of one of two adjacent methionines (codon 991 or 992) ( Delta Met991), in conjunction with silent ACA-->ACG change of codon 990. These two methionine residues are located in a highly conserved region of neurofibromin and are expected, therefore, to have a functional role in the protein. Our data represent results from the first study to correlate a specific small mutation of the NF1 gene to the expression of a particular clinical phenotype. The biological mechanism that relates this specific mutation to the suppression of cutaneous neurofibroma development is unknown.

[1]  G. Mortier,et al.  Comprehensive NF1 screening on cultured Schwann cells from neurofibromas , 2006, Human mutation.

[2]  C. Stewart,et al.  The laminopathies: the functional architecture of the nucleus and its contribution to disease. , 2006, Annual review of genomics and human genetics.

[3]  S. Huson,et al.  The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs) , 2006, Human mutation.

[4]  S. Adam,et al.  Nuclear lamins, diseases and aging. , 2006, Current opinion in cell biology.

[5]  H. Kehrer-Sawatzki,et al.  Spectrum of single‐ and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients , 2006, Genes, chromosomes & cancer.

[6]  B. Neel,et al.  Stops along the RAS pathway in human genetic disease , 2006, Nature Medicine.

[7]  D. Stevenson,et al.  Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype , 2006, Clinical genetics.

[8]  I. D'Angelo,et al.  A novel bipartite phospholipid‐binding module in the neurofibromatosis type 1 protein , 2006, EMBO reports.

[9]  A. Battaglia,et al.  NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. , 2005, American journal of human genetics.

[10]  Michael Krawczak,et al.  Microdeletions and microinsertions causing human genetic disease: common mechanisms of mutagenesis and the role of local DNA sequence complexity , 2005, Human mutation.

[11]  D. Horn,et al.  Childhood overgrowth in patients with common NF1 microdeletions , 2005, European Journal of Human Genetics.

[12]  L. Messiaen,et al.  Pitfalls of automated comparative sequence analysis as a single platform for routine clinical testing for NF1. , 2005, Journal of medical genetics.

[13]  A. Krainer,et al.  Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1 , 2004, Human mutation.

[14]  P. Tarpey,et al.  Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11–17 distinct from the GAP related domain , 2004, Journal of Medical Genetics.

[15]  D. Gutmann,et al.  Recent advances in neurofibromatosis type 1 , 2004, Current opinion in neurology.

[16]  Christopher Potts,et al.  Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors , 2004, Human mutation.

[17]  R. Tenconi,et al.  Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2 , 2004, Journal of Medical Genetics.

[18]  L. Kluwe,et al.  Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors , 2003, Human mutation.

[19]  D. Cooper,et al.  Evaluation of genotype-phenotype correlations in neurofibromatosis type 1 , 2003, Journal of medical genetics.

[20]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[21]  X. Estivill,et al.  Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients , 2003, Journal of medical genetics.

[22]  D. Baralle,et al.  Different mutations in the NF1 gene are associated with Neurofibromatosis–Noonan syndrome (NFNS) , 2003, American journal of medical genetics. Part A.

[23]  S. Pilotti,et al.  Elevated risk for MPNST in NF1 microdeletion patients. , 2003, American journal of human genetics.

[24]  D. Cooper,et al.  Meta‐analysis of indels causing human genetic disease: mechanisms of mutagenesis and the role of local DNA sequence complexity , 2003, Human mutation.

[25]  J. Friedman,et al.  Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1) , 2002, Genetic epidemiology.

[26]  D. Burns,et al.  Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[27]  M. Dorschner,et al.  Recombination hotspot in NF1 microdeletion patients. , 2001, Human molecular genetics.

[28]  T. Jacks,et al.  NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.

[29]  X. Estivill,et al.  Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. , 2000, Human molecular genetics.

[30]  J. Friedman,et al.  Growth in North American white children with neurofibromatosis 1 (NF1) , 2000, Journal of medical genetics.

[31]  C. Romano,et al.  Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. , 2000, American journal of medical genetics.

[32]  G Mortier,et al.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.

[33]  J. Szudek,et al.  Use of the National Institutes of Health Criteria for Diagnosis of Neurofibromatosis 1 in Children , 2000, Pediatrics.

[34]  P. Nürnberg,et al.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. , 2000, American journal of human genetics.

[35]  X. Estivill,et al.  Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. , 2000, Human molecular genetics.

[36]  Vladimir D. Gusev,et al.  On the complexity measures of genetic sequences , 1999, Bioinform..

[37]  V. Mautner,et al.  Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety , 1999, Neuroradiology.

[38]  R. Hughes Neurofibromatosis type 1 from genotype to phenotype: M. Upadhyaya and D. N. Cooper BIOS Scientific Publishers (230 pages), ISBN 1-859-961 91-6, £67.50, Hardback , 1999, Human Genetics.

[39]  R. Lehmann,et al.  Two independent mutations in a family with neurofibromatosis type 1 (NF1). , 1999, American journal of medical genetics.

[40]  Y. Shim Gene Structure and Function , 1998 .

[41]  D. Grobbee,et al.  Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 in children < or = 6 years and clinically suspected of having NF1. Neurofibromatosis team of Sophia Children's Hospital. , 1998, Journal of medical genetics.

[42]  A. Dachman,et al.  CT imaging in adults with neurofibromatosis‐1 , 1998, Neurology.

[43]  D. Cooper,et al.  Neurofibromatosis Type 1:: From Genotype to Phenotype , 1998 .

[44]  D. Cooper,et al.  Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay , 1998, Human Genetics.

[45]  J. Carey,et al.  Neurofibromatosis-Noonan syndrome. , 1998, American journal of medical genetics.

[46]  M. Weaver,et al.  Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. , 1997, American journal of medical genetics.

[47]  J. Tonsgard,et al.  Do NF1 gene deletions result in a characteristic phenotype? , 1997, American journal of medical genetics.

[48]  A. Crawford,et al.  Thoracic tumors in children with neurofibromatosis-1. , 1997, American journal of medical genetics.

[49]  J. Friedman,et al.  Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. , 1997, American journal of medical genetics.

[50]  M. Pöyhönen,et al.  Hereditary spinal neurofibromatosis: a rare form of NF1? , 1997, Journal of medical genetics.

[51]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[52]  W. Kabsch,et al.  Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras , 1996, Nature.

[53]  D. Cooper,et al.  Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene , 1996, Human Genetics.

[54]  Peter G. Korning,et al.  Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. , 1996, Nucleic acids research.

[55]  H. Saya,et al.  Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP‐dependent protein kinase , 1996, FEBS letters.

[56]  D. Evans,et al.  Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis , 1996, Clinical genetics.

[57]  B. Korf,et al.  Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. , 1995, American journal of medical genetics.

[58]  D. Abeliovich,et al.  Familial café au lait spots: a variant of neurofibromatosis type 1. , 1995, Journal of medical genetics.

[59]  W. Burke,et al.  Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. , 1994, American journal of human genetics.

[60]  P. Harper,et al.  Neurofibromatosis type 1 (NF1): the search for mutations by PCR-heteroduplex analysis on Hydrolink gels. , 1993, Human molecular genetics.

[61]  D. Easton,et al.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. , 1993, American journal of human genetics.

[62]  M. Tassabehji,et al.  Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome. , 1993, American journal of human genetics.

[63]  H. Brunner,et al.  Exclusion of the neurofibromatosis 1 locus in a family with inherited café-au-lait spots. , 1993, American journal of medical genetics.

[64]  D. Lilley Understanding DNA: The molecule and how it works , 1993 .

[65]  J. Charrow,et al.  Autosomal dominant multiple café-au-lait spots and neurofibromatosis-1: evidence of non-linkage. , 1993, American journal of medical genetics.

[66]  J. Farnham,et al.  Analysis of mutations at the neurofibromatosis 1 (NF1) locus. , 1992, Human molecular genetics.

[67]  B. Cohen Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, 2nd Ed. , 1992 .

[68]  V. Riccardi,et al.  Neurofibromatosis: Phenotype, Natural History and Pathogenesis , 1992 .

[69]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[70]  M. Boguski,et al.  cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. , 1991, Genomics.

[71]  J. Allanson,et al.  Watson syndrome: is it a subtype of type 1 neurofibromatosis? , 1991, Journal of medical genetics.

[72]  P. O’Connell,et al.  The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 , 1990, Cell.

[73]  S. Huson,et al.  Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales , 1988 .

[74]  Taylor,et al.  Model for the participation of quasi-palindromic DNA sequences in frameshift mutation. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[75]  V. M. Riccardi,et al.  Von Recklinghausen neurofibromatosis. , 1981, The New England journal of medicine.

[76]  M. Upadhyaya,et al.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience , 2006, Familial Cancer.

[77]  K. Khosrotehrani,et al.  Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients , 2005, American journal of medical genetics. Part A.

[78]  D. Cooper,et al.  Three different pathological lesions in the NF1 gene originating de novo in a family with neurofibromatosis type 1 , 2002, Human Genetics.

[79]  J M Friedman,et al.  NF1 gene and neurofibromatosis 1. , 2000, American journal of epidemiology.

[80]  M. Weaver,et al.  NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. , 2000, Human molecular genetics.

[81]  B. R. Korf,et al.  Plexiform neurofibromas. , 1999, American journal of medical genetics.

[82]  D. Cooper,et al.  The mutational spectrum in neurofibromatosis type 1 and its underlying mechanisms , 1998 .

[83]  C. V. van Asperen,et al.  Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype‐phenotype correlations in neurofibromatosis type 1? , 1997, Human mutation.

[84]  C. Calladine,et al.  Understanding DNA: The Molecule & How It Works , 1992 .

[85]  S. Huson Clinical and genetic studies of von Recklinghausen neurofibromatosis. , 1989 .

[86]  M. Inouye,et al.  Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday. , 1966, Cold Spring Harbor symposia on quantitative biology.

[87]  D. Grobbee,et al.  Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF 1 in children A 6 years and clinically suspected of having NF1 , 2022 .